| 货号 | 5443/50 |
| 别名 | 5-[4-(4-Cyano-1-butyn-1-yl)phenyl]- |
| 供应商 | Tocris |
| 生物活性 | High affinity and selective CB1 antagonist (Ki = 3.3 nM). Exhibits >100-fold selectivity for CB1 over CB2 receptors. Improves glucose homeostasis, reverses hepatic steatosis and reduces body weight in diet-induced obese mice. Orally available and non-brain penetrant. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 纯度 | >98 % |
| 计算分子量 | 556.46 |
| 分子式 | C26H23Cl2N5< |
| 可溶性/溶解性 | Soluble to 20 mM in DMSO |
| 参考文献 | Bowleset al (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc.Natl.Acad.Sci.U.S.A. 112 285. PMID: 25535367. Tamet al (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J.Clin.Invest. 120 2953. PMID: 20664173. |